Biocon
BIOCON · Pharma > Pharmaceuticals & Drugs · Chairman: Kiran Mazumdar-Shaw · MD: Siddharth Mittal · Listing date: April 8, 2004 · Employees: 13500 · Bangalore · http://www.biocon.com

Stock Price vs Company Growth
1d
0.1%
1w
2.4%
1m
2.2%
3m
6.8%
6m
17.8%
1y
3.8%
5y
2.4%
10y
17.9%
all
15.1%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 388 0.1%
337
425
Company Overview

Sales
16,476 Cr
Growth: 10.0%
Profit after Tax
447 Cr
Growth: 39.5%
Large Cap
51,934 Cr
P/E: 97.4x
Industry P/E: 33.3x
Fundamentals

Sales (Cr) ₹ 16,476
Growth 10.0%
EBITDA 20.7%
P/S 3.2x
Dividend 0.1%
P/E 97.4x
Book Value ₹ 163
PEG Ratio 9.7x
ROE 2.1%
P/B 2.4x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India (Lic)
4.11 %
Ahan- I Ltd
1.66 %
Qualified Institutional Buyer
0.61 %
Promoters
Kiran Mazumdar Shaw
39.62 %
Glentec International
19.76 %
John Mccallum Marshall Shaw
0.7 %
Ravi Rasendra Mazumdar
0.4 %
Yamini R Mazumdar
0.11 %
Others
Arun Suresh Chandavarkar
1.1 %
Beneficial Holdings Under Mgt-4
0.46 %
Iepf
0.01 %
Increase    Decrease    No change
Company Profile Detailed

The company is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe.
Investors (373)
Followers (42)